WASHINGTON TRUST Co boosted its stake in Amgen Inc. (NASDAQ:AMGN) by 2.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 49,471 shares of the medical research company’s stock after buying an additional 1,095 shares during the period. WASHINGTON TRUST Co’s holdings in Amgen were worth $12,309,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Wilkinson Global Asset Management LLC acquired a new stake in Amgen in the first quarter worth $61,201,000. Everence Capital Management Inc. bought a new position in shares of Amgen in the first quarter worth $3,453,000. Monument Capital Management grew its stake in shares of Amgen by 8.4% in the fourth quarter. Monument Capital Management now owns 9,548 shares of the medical research company’s stock worth $2,195,000 after purchasing an additional 743 shares in the last quarter. Great Lakes Advisors LLC grew its stake in shares of Amgen by 4.3% in the fourth quarter. Great Lakes Advisors LLC now owns 17,162 shares of the medical research company’s stock worth $3,946,000 after purchasing an additional 708 shares in the last quarter. Finally, Alpine Woods Capital Investors LLC grew its stake in shares of Amgen by 5.9% in the fourth quarter. Alpine Woods Capital Investors LLC now owns 32,393 shares of the medical research company’s stock worth $7,448,000 after purchasing an additional 1,795 shares in the last quarter. 75.23% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ:AMGN opened at $245.38 on Tuesday. The company has a current ratio of 2.28, a quick ratio of 1.88 and a debt-to-equity ratio of 3.12. The stock has a 50-day moving average price of $248.86 and a two-hundred day moving average price of $236.11. The stock has a market cap of $141.29 billion, a price-to-earnings ratio of 19.79, a PEG ratio of 1.90 and a beta of 0.76. Amgen Inc. has a 1 year low of $210.28 and a 1 year high of $276.69.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 8th. Investors of record on Monday, May 17th will be given a dividend of $1.76 per share. This represents a $7.04 annualized dividend and a yield of 2.87%. The ex-dividend date of this dividend is Friday, May 14th. Amgen’s dividend payout ratio is currently 47.50%.
AMGN has been the subject of several research reports. The Goldman Sachs Group reaffirmed a “buy” rating and set a $290.00 target price on shares of Amgen in a research note on Wednesday, April 28th. SVB Leerink decreased their price target on Amgen from $267.00 to $230.00 and set a “market perform” rating for the company in a research report on Tuesday. Credit Suisse Group decreased their price target on Amgen from $265.00 to $259.00 and set an “outperform” rating for the company in a research report on Tuesday. Oppenheimer decreased their price target on Amgen from $275.00 to $265.00 and set an “outperform” rating for the company in a research report on Monday. Finally, BMO Capital Markets decreased their price target on Amgen from $301.00 to $296.00 and set an “outperform” rating for the company in a research report on Wednesday, April 28th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and fourteen have issued a buy rating to the company. Amgen presently has an average rating of “Hold” and a consensus price target of $255.62.
In other news, EVP Jonathan P. Graham sold 11,110 shares of Amgen stock in a transaction dated Thursday, February 4th. The stock was sold at an average price of $236.51, for a total value of $2,627,626.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ronald D. Sugar sold 1,000 shares of Amgen stock in a transaction dated Wednesday, March 10th. The stock was sold at an average price of $231.53, for a total value of $231,530.00. Following the completion of the transaction, the director now directly owns 16,805 shares of the company’s stock, valued at $3,890,861.65. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 14,360 shares of company stock valued at $3,407,034. 0.36% of the stock is owned by corporate insiders.
Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA.
Featured Article: How is the discount rate different from the Federal Funds rate?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.